Jonathon Paul Fanning

Jonathon Paul Fanning

Auto-generated profile, based on publicly available information

Jonathon Paul Fanning

Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
JMJonathan E. Millar
Jonathan E. Millar
JFJonathon P. Fanning
Jonathon P. Fanning
CMCharles Ian McDonald
Charles Ian McDonald
DMDaniel F. McAuley
Daniel F. McAuley
John Francis FraserJohn Francis Fraser
John Francis Fraser
Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both. Over the last decade, the number of centres offering ECMO has grown rapidly. At the same time, the indications for its use have also been broadened. In part, this trend has been supported by advances in circuit design and in cannulation techniques. Despite the widespread adoption of extracorporeal life support techniques, the use of ECMO remains associated with significant morbidity and mortality. A complication witnessed during ECMO is the inflammatory response to extracorporeal circulation. This reaction shares similarities with the systemic inflammatory response syndrome (SIRS) and has been well-documented in relation to cardiopulmonary bypass. The exposure of a patient’s blood to the non-endothelialised surface of the ECMO circuit results in the widespread activation of the innate immune system; if unchecked this may result in inflammation and organ injury. Here, we review the pathophysiology of the inflammatory response to ECMO, highlighting the complex interactions between arms of the innate immune response, the endothelium and coagulation. An understanding of the processes involved may guide the design of therapies and strategies aimed at ameliorating inflammation during ECMO. Likewise, an appreciation of the potentially deleterious inflammatory effects of ECMO may assist those weighing the risks and benefits of therapy.

1 November 2014 in Stroke
Verified
Journal Article
Open access
PDF file
JFJonathon P. Fanning
Jonathon P. Fanning
AWAllan J. Wesley
Allan J. Wesley
AWAndrew A. Wong
Andrew A. Wong
JFJohn F. Fraser
John F. Fraser

1 February 2021 in European Heart Journal
Verified
Journal Article
Closed access
KWKei Woldendorp
Kei Woldendorp
BIBen Indja
Ben Indja
PBPaul G Bannon
Paul G Bannon
JFJonathon P Fanning
Jonathon P Fanning
BPBrian T Plunkett
Brian T Plunkett
SGStuart M Grieve
Stuart M Grieve
Background: Silent brain infarcts (SBIs) are frequently identified after transcatheter aortic valve implantation (TAVI), when patients are screened with diffusion-weighted magnetic resonance imaging (DW-MRI). Outside the cardiac literature, SBIs have been correlated with progressive cognitive dysfunction; however, their prognostic utility after TAVI remains uncertain. This study’s main goals were to explore (i) the incidence of and potential risk factors for SBI after TAVI; and (ii) the effect of SBI on early post-procedural cognitive dysfunction (PCD). Methods and results: A systematic literature review was performed to identify all publications reporting SBI incidence, as detected by DW-MRI after TAVI. Silent brain infarct incidence, baseline characteristics, and the incidence of early PCD were evaluated via meta-analysis and meta-regression models. We identified 39 relevant studies encapsulating 2408 patients. Out of 2171 patients who underwent post-procedural DW-MRI, 1601 were found to have at least one new SBI (pooled effect size 0.76, 95% CI: 0.72–0.81). The incidence of reported stroke with focal neurological deficits was 3%. Meta-regression noted that diabetes, chronic renal disease, 3-Tesla MRI, and pre-dilation were associated with increased SBI risk. The prevalence of early PCD increased during follow-up, from 16% at 10.0 ± 6.3 days to 26% at 6.1 ± 1.7 months and meta-regression suggested an association between the mean number of new SBI and incidence of PCD. The use of cerebral embolic protection devices (CEPDs) appeared to decrease the volume of SBI, but not their overall incidence. Conclusions: Silent brain infarcts are common after TAVI; and diabetes, kidney disease, and pre-dilation increase overall SBI risk. While higher numbers of new SBIs appear to adversely affect early neurocognitive outcomes, long-term follow-up studies remain necessary as TAVI expands to low-risk patient populations. The use of CEPD did not result in a significant decrease in the occurrence of SBI.

28 January 2014 in Circulation
Verified
Journal Article
Closed access
PDF file
JFJonathon P. Fanning
Jonathon P. Fanning
DWDarren L. Walters
Darren L. Walters
DPDavid Platts
David Platts
EEEamonn Eeles
Eamonn Eeles
JBJudith Bellapart
Judith Bellapart
JFJohn F. Fraser
John F. Fraser

22 September 2023 in Chest
Verified
Journal Article
Closed access
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
HLHui Min Lee
Hui Min Lee
ABAndrew Burke
Andrew Burke
GBGianluigi Li Bassi
Gianluigi Li Bassi
ATAntoni Torres
Antoni Torres
JFJonathon P. Fanning
Jonathon P. Fanning

20 August 2019 in Intensive Care Medicine Experimental
Verified
Journal Article
Open access
PDF file
KKKatrina K. Ki
Katrina K. Ki
MPMargaret Passmore
Margaret Passmore
CCChris H. H. Chan
Chris H. H. Chan
Maximilian Valentin MalfertheinerMaximilian Valentin Malfertheiner
Maximilian Valentin Malfertheiner
JFJonathon P. Fanning
Jonathon P. Fanning
JSJacky Suen
Jacky Suen
Extracorporeal membrane oxygenation (ECMO) is a life-saving modality used to manage cardiopulmonary failure refractory to conventional medical and surgical therapies. Despite advances in ECMO equipment, bleeding and thrombosis remain significant complications. While the flow rate for ECMO support is well recognized, less is known about the minimum-rate requirements and haemostasis. We investigated the relationship between different ECMO flow rates, and their effect on haemolysis and coagulation. Ten ex-vivo ECMO circuits were tested using donated, < 24-h-old human whole blood, with two flow rates: high-flow at 4 L/min (normal adult cardiac output; n = 5) and low-flow at 1.5 L/min (weaning; n = 5). Serial blood samples were taken for analysis of haemolysis, von Willebrand factor (vWF) multimers by immunoblotting, rotational thromboelastometry, platelet aggregometry, flow cytometry and routine coagulation laboratory tests. Low-flow rates increased haemolysis after 2 h (p = 0.02), 4 h (p = 0.02) and 6 h (p = 0.02) and the loss of high-molecular-weight vWF multimers (p = 0.01), while reducing ristocetin-induced platelet aggregation (p = 0.0002). Additionally, clot formation times were prolonged (p = 0.006), with a corresponding decrease in maximum clot firmness (p = 0.006). In an ex-vivo model of ECMO, low-flow rate (1.5 L/min) altered haemostatic parameters compared to high-flow (4 L/min). Observed differences in haemolysis, ristocetin-induced platelet aggregation, high-molecular-weight vWF multimers and clot formation time suggest an increased risk of bleeding complications. Since patients are often on ECMO for protracted periods, extended-duration studies are required to characterise long-term ECMO-induced haemostatic changes.